Novo Nordisk India strategy suffers semaglutide patent setback

The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer beats Novo Nordisk in $10bn bidding war

13 November 2025 US Federal Trade Commission’s antitrust warning tipped the scales in Pfizer’s favour, ending a heated dispute over a weight-loss biotech.

Americas

Novo Nordisk patent lapse opens door for Canadian Ozempic generics

17 June 2025 Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.

Americas

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

11 September 2024 Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.

More features

FedCirc voids Seagen patent in $41m cancer treatment dispute

Blank Rome expands team with Chicago partner

FisherBroyles grows IP practice with experienced patent attorney

New IP guidance promises to transform the NHS. Will it deliver?

UPC draws hard line on urgency in first SPC dispute

Patent and SPC litigator makes the move from Carpmaels

UPC appeals court hands Amgen a win in cholesterol dispute

Squires affirms USPTO’s stance on AI with revised guidance

Novo Nordisk India strategy suffers semaglutide patent setback

More on this story

Editor's picks

Editor's picks

More features